Roundtable of Longevity Clinics Year 3
Preview of Dec 6-8 @ Buck Institute for Longevity Research Napa Valley
The Roundtable of Longevity Clinics, taking place December 6–8, 2025, at the Buck Institute for Research on Aging, will bring together global leaders shaping the future of longevity medicine. Designed for clinic operators, researchers, investors, and health-tech innovators, this event focuses on translating emerging science into real-world practice—covering diagnostics, biomarkers, AI-driven health optimization, and regenerative care.
As the field of longevity continues to expand, one of our key goals is to define standards and best practices for this rapidly evolving discipline. Through sessions, case studies, and collaborative workshops, participants will explore how to deliver measurable outcomes in healthspan, integrate multi-biomarker testing, and create personalized care experiences that go beyond traditional wellness models.
In my sessions, I’ll be participating as both a panel speaker on Customer Experience and as a Moderator focused on the newest diagnostic breakthroughs in our longevity space. My goal is to challenge current assumptions across all four verticals, with a particular emphasis on profitability—executing on models of care that have demonstrated sustainable margins. While most longevity clinics are still in their infancy and many are experiencing early-stage cash burn, I believe the ultimate validation of these care models will come from their long-term sustainability.
This subspecialty has never been fully accepted by the traditional healthcare system. Without insurance reimbursement for preventative care, we’ve seen a consumer-driven revolution take place here in the U.S. A growing number of clinics within the vertical have received substantial investment and built strong niche markets over the past 10–15 years. Whether focused on therapeutics, diagnostics, tech platforms with virtual care, or concierge models, the field has been propelled forward by influential voices such as Dr. Peter Attia, MD, and others who continue to inspire both innovation and public interest.
In many ways, longevity medicine today is where IVF was two decades ago—though without the full advantage of AI. Having spent the past 30 years observing how new subspecialties evolve alongside waves of venture capital and innovation, I believe longevity will follow a familiar arc: periods of experimentation and correction that ultimately lead to consolidation, strategic partnerships, and economies of scale. What makes this moment so exciting is that we are laying the foundation for a discipline that will redefine proactive health and human vitality for generations to come.